Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | September 09, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date September 09, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2031-09-09 | Direct | 28,000 |
Reported balance
After 2021-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-09 · Grant · Acquired 28,000 · Balance 28,000 F1: 1/3 of the shares subject to the option will vest on September 9, 2022, and 1/36 of the shares subject to the option will vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the shares subject to the option will vest on September 9, 2022, and 1/36 of the shares subject to the option will vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2021 Filed Sep 14, 2021 00:13 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-055780 · doc4.xml · derivative · entry 1 JEW JEANNE Y · CIK 0001235946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-09-09 F1 · derivative.exercise_date: 1/3 of the shares subject to the option will vest on September 9, 2022, and 1/36 of the shares subject to the option will vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.